Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
12/09/2025
Insiders say Canada may drop oil emission caps in new climate plan.
Latest
2 m ago
The central parity rate of Renminbi against US Dollar is reported at 7.1019.
2 m ago
548 stocks were purchased with financing totaling over 100 million yuan, with Shenghong Technology ranking first with a purchase amount of 65.21 billion yuan.
3 m ago
The Ministry of Industry and Information Technology and two other departments issued the "Steady Growth Work Plan for the Electric Power Equipment Industry (2025-2026)".
3 m ago
According to Every Today AI News, Dongwu Securities released a research report on September 12, giving Jingsen Pharmaceutical (002020.SZ) a buy rating. The reasons for the rating mainly include: 1) The research pipeline of new drugs is gradually becoming more abundant, and small molecule LP (a) inhibitors have the potential to go global; 2) The insomnia drug Daiduoxin has been listed and trading volume has increased significantly, contributing to an increase in performance; 3) Existing business maintains steady growth, and blockbuster first generics such as Calilazine will contribute to future growth. (Daily Economic News)
3 m ago
According to a report released by Shanxi Securities on September 11th, Sunshine Power (300274.SZ) has been given a buy rating. The main reasons for this rating include: 1) the income from photovoltaic inverters continues to grow, with global competitiveness steadily increasing; 2) revenue from energy storage systems has more than doubled year-on-year, and profitability remains high; 3) continuous increase in research and development investment, with comprehensive layout of AIDC. (Daily Economic News)
See all latest